Page last updated: 2024-12-05

3-Hydroxy-alpha-methyl-DL-tyrosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID4138
CHEMBL ID718
CHEBI ID180994
SCHEMBL ID196981

Synonyms (106)

Synonym
dl-alpha-methyl dopa
racemic alpha-methyldopa
alanine, 3-(3,4-dihydroxyphenyl)-2-methyl-, dl-
metholes
(+-)-alpha-methyldopa
dl-tyrosine, 3-hydroxy-alpha-methyl-
einecs 209-088-7
3-hydroxy-alpha-methyl-dl-tyrosine
mulfasin
HMS3266O08
CHEBI:180994
2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid
55-40-3
alanine,4-dihydroxyphenyl)-2-methyl-, l-(-)-
.alpha.-methyldopa
alanine,4-dihydroxyphenyl)-2-methyl-, l-
.alpha.-methyl dopa
.alpha.-methyldopa, l-
l-(-)-.alpha.-methyl-.beta.-(3,4-dihydroxyphenyl)alanine
l-(.alpha.-md)
l-.alpha.-methyl-(3,4-dihydroxyphenyl)alanine
l(-)-.beta.-(3,4-dihydroxyphenyl)-.alpha.-methylalanine
.alpha.-methyl-l-(3,4-dihydroxyphenyl)alanine
wln: qvxz1&1r cq dq
.alpha.-methyl-.beta.-(3,4-dihydroxyphenyl)-l-alanine
EU-0100770
(+/-)-3-(3,4-dihydroxyphenyl)-2-methyl-dl-alanine
einecs 200-232-4
LOPAC0_000770
NCGC00094109-01
NCGC00094109-02
(?)-3-(3,4-dihydroxyphenyl)-2-methyl-dl-alanine
3-(3,4-dihydroxyphenyl)-2-methyl-dl-alanine
M-3586
NCGC00015631-03
M 7277
AC-11788
dl-alpha-methyl-dopa
( inverted question mark)-3-(3,4-dihydroxyphenyl)-2-methyl-dl-alanine
NCGC00015631-05
2-amino-3-(3,4-dihydroxy-phenyl)-2- methyl-propionic acid(catechol metabolite)
methyldopa dl-form
methyldopa (racemic)
racemic .alpha.-methyldopa
CHEMBL718
dl-.alpha.-methyl dopa
dl-methyldopa
L001029
AKOS003273681
HMS3262I22
HMS3259C21
A830691
555-29-3
CCG-204855
methyldopa anhydrous, (+/-)-
unii-33td13t99r
33td13t99r ,
3-hydroxy-alpha-methyltyrosine
NCGC00015631-04
FT-0671717
FT-0671718
FT-0604487
FT-0603468
LP00770
methyldopa dl-form [mi]
dl-.alpha.-methyl-3-(3,4-dihydroxyphenyl)alanine
(+/-)-.alpha.-methyldopa
2-(3,4-dihydroxybenzyl)-2-aminopropanoic acid
(+/-)-methyldopa
dl-2-methyl-3-(3,4-dihydroxyphenyl)alanine
AKOS017258656
NC00520
SCHEMBL196981
NCGC00261455-01
tox21_500770
(y)-3-(3,4-dihydroxyphenyl)-2-methyl-dl-alanine
2-amino-2-methyl-3-(3,4-dihydroxyphenyl)propionic acid
W-105556
l-(-)-.beta.-(3,4-dihydroxyphenyl)-.alpha.-methylalanine
methyl-dopa
.alpha.-medopa
elanpres
equibar
AC-8433
sr-01000075631
SR-01000075631-1
sr-01000076007
SR-01000076007-1
SR-01000075631-3
SBI-0050748.P004
2,2,3,4,4-pentabde
alpha-methyl-3,4-dihydroxy-dl-phenylalanine
BCP28393
SDCCGSBI-0050748.P005
NCGC00015631-09
DTXSID60970356
Q27256299
methyln-4-boc-n-1-cbz-2-piperazinecarboxylate
d-?-methyl dopa
rac ?-methyl dopa
rac alpha -methyl dopa
rac alpha-methyl dopa
( inverted exclamation marka)-alpha-methyldopa
alpha-methyl-dl-beta-3,4-dihydroxyphenylalanine
2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoicacid
EN300-297472

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" LD50 studies in mice have established that 6-OH-alpha-Me-Dopa is over four times more toxic than alpha-Me-Dopa."( Synthetic and preliminary hemodynamic and whole animal toxicity studies on (R,S)-, (R)-, and (S)-2-methyl-3-(2,4,5-trihydroxyphenyl)alanine.
Castagnoli, N; Cheng, A; Karashima, D; Melmon, KL; Musson, DG; Rubiero, H, 1980
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (24)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.84220.003245.467312,589.2998AID1705; AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.63100.004023.8416100.0000AID485290
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency11.19360.140911.194039.8107AID2451
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency3.54810.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency3.16230.125919.1169125.8920AID2549
thioredoxin reductaseRattus norvegicus (Norway rat)Potency8.29150.100020.879379.4328AID488773; AID588453
GLS proteinHomo sapiens (human)Potency11.22020.35487.935539.8107AID624146
Microtubule-associated protein tauHomo sapiens (human)Potency3.24650.180013.557439.8107AID1460; AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency2.23870.011212.4002100.0000AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency10.62130.531815.435837.6858AID504845
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.87050.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency25.11890.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency95.283423.934123.934123.9341AID1967
D(1A) dopamine receptorHomo sapiens (human)Potency3.26410.02245.944922.3872AID488982
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency10.00000.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency5.32330.006026.168889.1251AID488953
DNA polymerase betaHomo sapiens (human)Potency5.62340.022421.010289.1251AID485314
flap endonuclease 1Homo sapiens (human)Potency2.37780.133725.412989.1251AID488816; AID588795
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency12.58930.050127.073689.1251AID588590
DNA polymerase kappa isoform 1Homo sapiens (human)Potency1.88880.031622.3146100.0000AID588579
M-phase phosphoprotein 8Homo sapiens (human)Potency40.90530.177824.735279.4328AID488949
phosphoglycerate kinaseTrypanosoma brucei brucei TREU927Potency3.01310.07578.474229.0628AID504547
2,3-bisphosphoglycerate-independent phosphoglycerate mutaseLeishmania major strain FriedlinPotency30.13137.568615.230621.3313AID504548
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.53580.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (24)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID116921Compound was tested for toxicity (lethal dose) in male white swiss mice1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Synthetic and preliminary hemodynamic and whole animal toxicity studies on (R,S)-, (R)-, and (S)-2-methyl-3-(2,4,5-trihydroxyphenyl)alanine.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (6.25)18.7374
1990's0 (0.00)18.2507
2000's2 (12.50)29.6817
2010's7 (43.75)24.3611
2020's6 (37.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.99 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]